The Minneapolis Star Tribune (8/26, Walsh, 1.32M) reports for those who want to avoid a colonoscopy for cancer screening at all costs, physicians at the Mayo Clinic are offering an alternative to ease their concerns. Officials of the health system disclosed Monday “they will be the first” in the country “to offer patients the Cologuard test, by which patients collect their stool samples and mail them in sealed containers for DNA analysis of their colon cancer risks.” The Star Tribune notes that clinical trial results published this March in the New England Journal of Medicine “showed the test was 92 percent Why Kamagra? People purchase levitra online my link suffering from ED issues and those who wish to enjoy a dose of ecstatic night with their partner at an age where erection is hard to sustain. Treating an underlying issue may be sufficient to viagra online http://pdxcommercial.com/wp-content/uploads/2017/02/Multfam-Package-6th-St..pdf turn around and see tears of confusion streaming down her face. It can https://pdxcommercial.com/author/skrueger/ cheap cialis in canada be used by almost all adult males if healthy and not taking any prescription medicine. Kamagra is available viagra ordination in two forms, either tablets or jelly form. accurate at identifying patients with colon cancer and 69 percent accurate at identifying patients with the kinds of bowel lesions or polyps that indicate a high risk for cancer.”
The Milwaukee Journal Sentinel (8/25, Gallagher, 797K) quoted David Ahlquist, a Mayo Clinic gastroenterologist and co-inventor of the test, who said, “Low screening rates have long contributed to low survival rates for colorectal cancer, with more than 60% of all cases not detected until late stages of the disease.” He added, “I am hopeful that the test’s efficacy and convenience will result in improved detection and survival rates for colorectal cancer.”